We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
For anyone not seen, search for IQAI for the new message board
My shares are with Barclays. There is clearly a mistake with the system cos my shares are showing as worth 109,000 pounds. Hope I can make that one day !
Farewell FBDU, Hello IQAI!
Iqai is not showing up on the Lse site maybe tomorrow ?
Thanks, not checked in for a while, only a small amount invested
change of name Iq-ai
Is this share suspended this morning?
ZUCHWIL, SWITZERLAND - Merrick, a leading global manufacturer of biotechnology products and recognized innovator in automated medical robotic systems, today announced a definitive agreement to acquire AI Medical Systems, GmbH., founded in 2016 by Silicon Valley entrepreneur Philip Odegard. Merrick will acquire all of the outstanding capital stock of AI Medical, which is privately-owned and based in Zurich, Switzerland, for approximately CHF 2.3 Billion ($2,318,515,000 USD). The acquisition marks the second successful Artificial Intelligence buyout in Philip Odegard’s expansive technology portfolio. Odegard’s more notable early investments include the likes of Silicon Valley’s UBER, Facebook and Tesla.
The AI Medical transaction, subject to customary closing conditions, including receipt of certain regulatory approvals, is expected to be completed in the fourth calendar quarter of 2018. AI Medical is a technology-led company, focused solely on the design and manufacture of dependable, life improving Artificial Intelligence and machine learning software coupled with robotic hardware that are affordable for caregivers worldwide. One key way Artificial Intelligence benefits is with diagnostic and imaging tools, like MRIs and CT and PET scans. Algorithms can be trained to accurately measure all of the lymph nodes from a cancer patient's CT scan to see if they're changing size. It's a huge job that algorithms can do much more quickly than humans.
Merrick’s acquisition of AI Medical Systems includes their proprietary first-to-market artificial intelligence algorithms and machine learning – the science of getting computers to act without being programmed by humans. One such algorithm is called a neural network because it can learn and improve performance on its own like the human brain, but can work much faster. Collectively, these powerful acquired tools will help find disease almost before a patient is symptomatic, treat it early, and achieve a higher survival rate with less patient suffering and at reduced cost.
AI Medical’s products are sold in Europe and more than 115 countries worldwide, with a surging demand in the United Arab Emirates. “This acquisition is consistent with Merrick’s strategy to expand into adjacencies and invest in product categories where it can develop global competitive advantages,” said Amanda Eriksen, President, Robotics & Monitoring Systems, Merrick. “AI Medical’s products and technology complement the Company’s current portfolio of healthcare biotechnology solutions and will broaden our software platform for patients around the world, particularly in emerging markets.” Assuming a closing in the fourth calendar quarter of 2018, Merrick does not expect this transaction to have a material impact on its fiscal 2018 sales, operating margin or earnings per share. Once the transaction has been completed, Merrick will report the AI Medical business as part of its Software & Automated Machinery product line in the Medical D
David is a truly inspiring senior executive whom delivered exceptional results through his excellent leadership values. The proven financial results of the Hospital Group is a true testament of David's executive leadership style. He has an exceptional ability to develop successful business partnerships with our suppliers and customers.
President & CEO, Founder
Tenaxis Medical Inc
October 2004 – November 2011 7 years 2 months
Tenaxis Medical Inc was founded in 2004 and develops and manufactures surgical sealants. Its first product, ArterX , a surgical sealant, was launched in Europe in 2009, was awarded a PMA and will be launched in the USA in 2013. Raised over $25M from private investors.
Tenaxis Medical Inc was sold to The Medicines Company (NASDAQ:MDCO) for $168M in May 2014;
some serious big players in this industry like Fujifilm, Siemens healthcare, Toshiba, Philips, GE healthcare, Facebook medical, Google healthcare, Hitachi medical. these guys have got serious money to spend.
dunno. but the costs here are low and they are predicting $250,000 per quarter revenue from 2019 once they get IB products all onto DICOM viewer. look at the recent revenue figures. they had done double the revenue in half the time. revenue of £1.5 mill for FY 2019 won't surprise me. add a few bolt on acquisitions might even go higher. also we are standard list and not aim. being standard list has got to attract better institutions to invest. there's a lot happening in the space.
There are a list of items that with each add value to the share price as they happen over the next 3-12months: - increased director stakebuilding - fda approval - commercial plans - commercial sales - further aqusitions - further results from acedemic partners - takeover As each of these items are ticked off we will see the doubling and trebling of the sp. they are not necessary in any order but they are part of the jigsaw to the final item which is a takeover. SL
Agree draft - the question is how long will it take for there to be multiple returns?
Really undervalued here and we are Main Market and not aim like the other UK listed companies.
Scientific Digitial £37m
Polarean £13m
Ixico £12m
feedback £5m
IQ-AI £3m
I think IQ-AI with its buy and build strategy, TB in charge, low free float, All eyes on medical AI space, I can see multiples return here
BenevolentAI
BenevolentTech, part of the biotech business BenevolentAI, is developing an advanced AI platform to help scientists make new discoveries and redefine how they use the data available to them to drive innovation.
The technology is built on a deep learning judgement system that generates usable knowledge from vast amounts of information in scientific papers, patents, clinical trial information and from structured data sets. The technological goal is to augment human judgment so technology could assist the creative processes that characterise the very best scientists.
BenevolentAI is hoping to combine the power of machine brains with expert human brains to enable previously impossible scientific discoveries.
Cambridge Cognition is a neuroscience-focused digital health company which develops products and services with the aim of better understanding, detecting and treating conditions that affect brain health. It creates cognitive research technologies for mobile, wearable and online platforms which have the potential to accelerate new treatment development, improve research efficiency and measure cognitive health and wellbeing in patients on a global scale.
The company’s technology can measure digital cognitive biomarkers to track the improvement or decline in health of patients with conditions such as Alzheimer’s, Parkinson’s, depression, schizophrenia and ADHD. Its customers include global pharmaceutical and biotechnology companies, contract research organisations and academic research institutions.
DeepMind Technologies
Founded in September 2010, DeepMind Technologies is a British AI company. It was acquired by Google in 2014 but is still has its headquarters in London. The company is a self-proclaimed world leader in AI research and its application in areas such as healthcare and energy.
The DeepMind Applied team has collaborated with clinicians in the NHS with the aim of delivering better care for numerous conditions that affect millions of people worldwide, including cancer. It aims to use AI to radically improve healthcare but also believes the scientific advances being made could tackle other global problems, such as climate change, by creating a quicker platform to find solutions.
BenevolentAI
BenevolentTech, part of the biotech business BenevolentAI, is developing an advanced AI platform to help scientists make new discoveries and redefine how they use the data available to them to drive innovation.
The technology is built on a deep learning judgement system that generates usable knowledge from vast amounts of information in scientific papers, patents, clinical trial information and from structured data sets. The technological goal is to augment human judgment so technology could assist the creative processes that characterise the very best scientists.
BenevolentAI is hoping to combine the power of machine brains with expert human brains to enable previously impossible scientific discoveries.
Earlier this year, British Prime Minister Theresa May announced plans to increase the use of data and artificial intelligence (AI) to transform the diagnosis of chronic diseases in Britain.
The plans involve using emerging technologies to cross-reference patient genetics, habits and medical records with national data so that cancer can be easier to detect in its early stages. It is hoped this will result in at least 50,000 people each year receiving an earlier diagnosis of prostate, ovarian, lung or bowel cancer. May also stressed that successful implementation of the plans could create a whole new industry around AI in healthcare, potentially leading to new jobs.
With investment likely to increase and the government throwing its support behind AI in healthcare, the UK medical technology industry looks set to grow. But who are the star UK performers in the field of AI-enhanced health technology? Below are some of the top UK medical technology companies currently dominating the healthcare AI field.
Skin Analytics
This computer vision company aims to make the diagnosis of melanoma easier, making it exactly the kind of company the government is looking to support, with the AI initiative’s aim of 22,000 fewer people dying from cancer each year by 2033.
Skin Analytics builds a digital history of a patient’s skin so that any potentially cancerous changes, such as new skin lesions or moles, can be tracked. Patients can use the Skin Analytics smartphone app, called 4ev, for the tracking of their skin. The technology uses algorithms to measure how the skin is changing based on smartphone images taken by the individual. Treatment options can then be identified, evaluated and informed across a range of consumer health and clinical skin conditions.
Babylon Health
Founded by British entrepreneur Ali Parsa in 2013, Babylon is a mobile healthcare app and healthcare service provider, self-described as a convenient way to access NHS healthcare. It allows healthcare professionals to have virtual conversations with patients via text messages and videos and continues to build on its AI capabilities, such as diagnosis by AI. Patients can receive referrals, prescriptions, order test kits and sick notes and book appointments with local facilities through the service.
Babylon says it covers all NHS primary care services including the management of acute and chronic diseases. It current only works in partnership with healthcare practices in London but aims to expand. In April 2017, Babylon Health announced it had raised around £50m to develop its AI diagnosis tool, which the company said could reduce the cost of a consultation by as much as 80%.
Cambridge Cognition
Cambridge Cognition is a neuroscience-focused digital health company which develops products and services with the aim of better understanding, detecting and treating conditions that affect brain health. It creates cognitive research technologies for mobile, wearable and online pl
We will rise by the 9 th or maybe after. The name change has to make a difference. It did with bloc
this is the hot space right now in medical AI.
to see buys coming in from the bell. Interest building nicely 2.4-2.5. 3p relatively soon as a start point. SL
think we will do very well higher. interestingly NTTDATA a billion $ company just invested in Deeptek. medical AI.
New name approved from 9th oct